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Abstract
Background: A direct pharmacological stimulation of soluble guanylate cyclase (sGC) is an emerging therapeutic approach
to the management of various cardiovascular disorders associated with endothelial dysfunction. Novel sGC stimulators,
including riociguat (BAY 63-2521), have a dual mode of action: They sensitize sGC to endogenously produced nitric oxide
(NO) and also directly stimulate sGC independently of NO. Little is known about their effects on tissue remodeling and
degeneration and survival in experimental malignant hypertension.
Methods and Results: Mortality, hemodynamics and biomarkers of tissue remodeling and degeneration were assessed in
Dahl salt-sensitive rats maintained on a high salt diet and treated with riociguat (3 or 10 mg/kg/d) for 14 weeks. Riociguat
markedly attenuated systemic hypertension, improved systolic heart function and increased survival from 33% to 85%.
Histological examination of the heart and kidneys revealed that riociguat significantly ameliorated fibrotic tissue remodeling
and degeneration. Correspondingly, mRNA expression of the pro-fibrotic biomarkers osteopontin (OPN), tissue inhibitor of
matrix metalloproteinase-1 (TIMP-1) and plasminogen activator inhibitor-1 (PAI-1) in the myocardium and the renal cortex
was attenuated by riociguat. In addition, riociguat reduced plasma and urinary levels of OPN, TIMP-1, and PAI-1.
Conclusions: Stimulation of sGC by riociguat markedly improves survival and attenuates systemic hypertension and systolic
dysfunction, as well as fibrotic tissue remodeling in the myocardium and the renal cortex in a rodent model of pressure and
volume overload. These findings suggest a therapeutic potential of sGC stimulators in diseases associated with impaired
cardiovascular and renal functions.
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Introduction
Tissue remodeling and degeneration ultimately resulting in a
loss of function are observed in various organs including the heart,
kidneys and vasculature in malignant arterial hypertension.
Osteopontin (OPN), plasminogen activator inhibitor-1 (PAI-1)
and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) are
among the pro-fibrotic mediators that have been attributed to
tissue degeneration and progression of cardiovascular disease.
Preclinical and clinical evidence indicates that increased levels of
these mediators are associated with a loss of function of several
target organs including the heart and kidneys [1,2]. Osteopontin,
also called secreted phosphoprotein-1 or uropontin, is a cytokine-
like pro-fibrotic mediator that stimulates extracellular matrix
formation thus contributing to tissue remodeling [3]. Increased
production of OPN has recently been shown to correlate with the
severity of chronic heart failure and pulmonary hypertension (PH),
and it is an independent predictor of death [4,5]. In addition,
OPN is attributed to the loss of renal function in patients with
chronic kidney disease [6]. Likewise, an up-regulation of PAI-1
expression in the myocardium and vasculature is associated with
increased accumulation of extracellular matrix and progression of
cardiovascular disease [7]. Elevated plasma levels of PAI-1 also
predict cardiovascular events and cardiovascular mortality in
dialysis patients [8,9]. Similarly, increased circulating TIMP-1
levels are associated with end-organ tissue remodeling and
progression of cardiovascular and renal diseases [9,10].
A novel pharmacological principle for treatment of different
forms of cardiovascular disease and PH is based on the direct
stimulation of the soluble guanylate cyclase (sGC) [11,12,13]. The
present study was conducted to evaluate the effects of the new,
selective and highly potent sGC stimulator riociguat on cardiac
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21853and renal tissue remodeling and organ function under conditions
of chronic pressure and volume overload. Riociguat has a dual
mode of action: it sensitizes sGC to endogenously produced nitric
oxide (NO), while also directly stimulating sGC independently of
NO [13]. Riociguat has been shown to improve hemodynamics
and provide end-organ protection in several experimental models
of PH and renal failure [14,15]. The drug is currently undergoing
phase III clinical trials in patients with pulmonary arterial
hypertension and chronic thromboembolic pulmonary hyperten-
sion, having shown encouraging results in non-randomized
studies.
Results
Survival rate, body weight, and hemodynamics
The mortality of salt-loaded rats was significantly decreased in
the riociguat-treated groups compared to the animals receiving
vehicle alone. Only seven out of 21 (33%) vehicle-treated animals
survived until the end of the study. In both of the riociguat-treated
groups only two out of 13 rats died during the course of the study
(85% survival) (p,0.05 vs. the vehicle group; Figure 1A). During
the observation period the body weight of the vehicle group
increased by 36.7616.3 g, whereas the body weight of animals
treated with riociguat 3 or 10 mg/kg/d increased by 58.166.4 g
and 57.269.2 g, respectively (Figure 1B). Systolic blood pressure
and heart rate were measured before starting the treatments and at
several time points during the study, as depicted in the Figures 1C
and 1D. During the first six weeks systolic blood pressure increased
in all groups. In the vehicle-treated animals a maximum increase
in systolic blood pressure was noted by week 7, and it was
32.867.6 mmHg above the baseline at the end of the study. In
contrast, systolic blood pressure returned to the baseline in the
animals treated with riociguat 3 mg/kg/d (0.763.0 mmHg)
and was slightly reduced by riociguat 10 mg/kg/d (212.36
4.5 mmHg). No significant changes in heart rate were obser-
ved.The body weight and relative organ weights (related to body
weight) are presented in Table 1. The relative weights of the
hearts, the left ventricles, and both kidneys were significantly lower
in the animals treated with riociguat 10 mg/kg/d when compared
to the vehicle group.
Cardiac echocardiographic measurements
The results of cardiac echocardiographic measurements are
summarized in Table 2. Overall, riociguat significantly improved
Figure 1. Effects of riociguat on survival (A), body weight (B), systolic blood pressure (C) and heart rate (D) in Dahl/ss rats
maintained on a high-salt diet. Vehicle- (n=21) and riociguat-treated (3 or 10 mg/kg/d, n=13 per group) rats were observed for 14 weeks. Data
are mean6SEM; *p,0.05, ***p,0.001 vs. the vehicle-treated animals.
doi:10.1371/journal.pone.0021853.g001
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treated controls. Fractional shortening was markedly reduced in
the vehicle group, whereas it was maintained within the normal
range by riociguat (p,0.05). While the relative increases in
thickness of the intraventricular septum and the left free wall
nearly doubled, the left free wall to intraventricular septum ratio
and the ventricular diameters in diastole and systole were
significantly reduced by riociguat (p,0.05).
Plasma and urinary biochemical markers
Blood samples were obtained at the end of the study (Table 3).
No significant intergroup differences were observed in plasma
concentrations of ALT, GLDH, LDH, CK, creatinine, urea,
protein, albumin, plasma renin activity or angiotensin I. Plasma
concentrations of uric acid, AST, and the natriuretic peptides
ANP and BNP were significantly reduced by riociguat (p,0.05).
Urine samples were taken before starting treatments and at the
end of the study. There were no significant intergroup differences
in renal function parameters at the beginning of the study (data
not shown). At the termination of the study (Table 4), diuresis and
urinary excretion of urea, protein, Na
+ and K
+ were significantly
reduced by riociguat as compared to the vehicle-treated controls
(p,0.05). In contrast, urinary excretion of cGMP was markedly
increased in both riociguat-treated groups (p,0.05).
mRNA expression of pro-fibrotic biomarkers
The gene expression of the pro-fibrotic biomarkers OPN,
TIMP-1 and PAI-1 were determined in the hearts and kidneys of
the pressure- and volume-overloaded Dahl/ss rats (Figure 2).
Compared to healthy control animals, the relative increase in
mRNA expression of the pro-fibrotic biomarkers was detected in
all tissue samples in the vehicle group. In particular, mRNA
expression of PAI-1 and TIMP-1 was significantly increased in the
renal cortex (p,0.05). Treatment with riociguat prevented the
mRNA up-regulation of OPN, TIMP-1, and PAI-1 in the renal
cortex (p,0.05). Riociguat also attenuated mRNA expression of
OPN, TIMP-1, and PAI-1 in the left ventricle.
Protein expression of pro-fibrotic biomarkers
Protein expression of OPN, TIMP-1, PAI-1 in plasma and urine
was markedly elevated following salt loading (Figure 3). This
increase in protein expression of the pro-fibrotic biomarkers was
significantly reduced by riociguat (p,0.05).
Histopathology
Histopathological evaluation of the kidneys and the hearts of the
vehicle- and riociguat-treated rats was performed in order to
elucidate effects of riociguat on tissue fibrosis (Table 5). The
vehicle-treated animals demonstrated a profound tubulopathy in
Table 1. Organ weights in the vehicle- and riociguat-treated Dahl/ss rats maintained on a high-salt diet.
Vehicle (n=17) Riociguat (3 mg/kg/d) (n=13) Riociguat (10 mg/kg/d) (n=13)
Body weight (g) 385616 40166 40169
Relative heart weight (g/kg) 4.460.3 4.160.3 3.760.1**
Relative left ventricle weight (g/kg) 3.360.2 3.060.2 2.760.1*
Relative right ventricle weight (g/kg) 0.660.02 0.760.09 0.660.01
Relative left kidney weight (g/kg) 5.160.3 4.560.1** 4.260.1***
Relative right kidney weight (g/kg) 5.360.3 4.460.1** 4.260.08***
Measurements were obtained at the study end. Data are mean6SEM;
*p,0.05,
**p,0.01,
***p,0.001 vs. the vehicle-treated animals.
doi:10.1371/journal.pone.0021853.t001
Table 2. Cardiac echocardiographic measurements in the vehicle- and riociguat-treated Dahl/ss rats maintained on a high-salt
diet.
Vehicle (n=17) Riociguat (3 mg/kg/d) (n=13) Riociguat (10 mg/kg/d) (n=13)
Fractional shortening (%) 19.761.8 43.961.8*** 46.562.2***
Relative increase in thickness of IVS (%) 28.265.5 53.965.6** 54.564.4**
Relative increase in thickness of LfW (%) 29.067.1 45.866.1* 61.666.0**
LfW:IVS 1.460.1 1.260.1* 1.060.03***
LfW diastole (mm) 2.360.1 2.660.1* 2.260.1
LVD diastole (mm) 8.960.2 7.760.3** 7.960.1**
IVS diastole (mm) 1.760.1 2.360.1*** 2.260.1***
LVD systole (mm) 7.260.2 4.460.3*** 4.260.2***
IVS=intraventricular septum, LfW=left free wall, LVD=left ventricular diameter in diastole or systole. Measurements were obtained at the study end. Data are
mean6SEM;
*p,0.05,
**p,0.01,
***p,0.001 vs. the vehicle-treated animals.
doi:10.1371/journal.pone.0021853.t002
Cardio-Renal Protection of Riociguat in Dahl Rats
PLoS ONE | www.plosone.org 3 July 2011 | Volume 6 | Issue 7 | e21853the renal cortex and extensive myocardial fibrosis in the
subendocardial regions of the left ventricle. Treatment with
riociguat attenuated degenerative and inflammatory changes in
the kidneys and the heart. Histopathological examination of the
kidneys revealed that riociguat significantly reduced glomerulo-
sclerosis and interstitial and perivascular fibrosis compared to the
vehicle-treated rats. Likewise, cardiac histopathology revealed that
interstitial fibrosis and myocyte diameter were significantly
decreased in the riociguat-treated animals compared to the vehicle
group. No significant changes were found in the degree of cardiac
perivascular fibrosis.
Discussion
The recent discovery of sGC stimulators including riociguat
(BAY 63-2521) offers an attractive option for the management of
cardiovascular disease associated with underlying endothelial
dysfunction. This novel therapeutic approach is based on a
molecular mechanism that is fundamentally different from
established vascular targets [12,16]. Riociguat has a dual mode
of action: it sensitizes sGC to endogenously produced NO and
can also increase sGC activity in the absence of NO, causing
vasorelaxation and anti-proliferative and anti-fibrotic effects.
This dual mode of action is biologically important because the
NO levels are decreased in various cardiopulmonary diseases
[11,12]. Importantly, in addition to its regulatory effects on
vascular tone, NO may also exert numerous cytotoxic effects,
largely attributed to the reactive oxidant peroxynitrite, which is
formed from the diffusion-controlled reaction of NO with
superoxide. Peroxynitrite interacts with lipids and proteins,
altering cellular signaling, disrupting mitochondrial function,
and damaging DNA, which can eventually lead to cellular
dysfunction and death [17]. Hence, the novel pharmacological
strategy of direct sGC stimulation may circumvent potentially
Table 3. Plasma biochemical measurements in the vehicle- and riociguat-treated Dahl/ss rats maintained on a high-salt diet.
Vehicle (n=17) Riociguat (3 mg/kg/d) (n=13) Riociguat (10 mg/kg/d) (n=13)
AST (U/L) 109618 7364* 8067*
ALT (U/L) 77696 6 636 3 64
GLDH (U/L) 24671 4 621 6 63
LDH (U/L) 5236123 505650 398656
CK (U/L) 282648 310622 250630
Creatinine (mmol/l) 51634 8 615 0 61
Urea (mmol/l) 7.461.0 7.860.5 9.260.4
Protein (g/l) 63616 2 60.4 6260.7
Uric acid (mmol/L) 53682 4 62*** 2863**
Albumin (g/L) 2760.7 2860.5 2960.7
PRA (ng/ml/h) 1.560.3 1.760.4 1.360.3
Angiotensin I (ng/ml) 0.660.1 0.660.1 0.560.1
ANP (pg/ml) 121645 36616** 2065**
BNP (pg/ml) 1664 7.962.6* 6.261.0*
AST=aspartate amino transferase, ALT=alanine amino transferase, GLDH=glutamate dehydrogenase, LDH=lactate dehydrogenase, CK=creatinine kinase,
PRA=plasma renin activity, ANP=atrial natriuretic peptide, BNP=B-type natriuretic peptide. Data are mean6SEM;
*p,0.05,
**p,0.01,
***p,0.001 vs. the vehicle-treated animals.
doi:10.1371/journal.pone.0021853.t003
Table 4. Parameters of renal function in the vehicle- and riociguat-treated Dahl/ss rats maintained on a high-salt diet.
Vehicle (n=17) Riociguat (3 mg/kg/d) (n=13) Riociguat (10 mg/kg/d) (n=13)
Diuresis (ml/kg/h) 4.760.7 1.660.2*** 1.560.2***
Creatinine (mmol/kg/h) 9.660.8 1160.8 1160.8
Urea (mmol/kg/h) 7876136 243632*** 207648***
Protein (mg/kg/h) 3164.8 1862.6** 9.562.0***
Na
+ (mmol/kg/h) 9106199 282650** 259659**
K
+ (mmol/kg/h) 230634 147613* 149619*
cGMP (pmol/h) 8806145 33176355*** 41516491***
Measurements were obtained at the study end (collection period of 8 hrs). Data are mean6SEM;
*p,0.05,
**p,0.01,
***p,0.001 vs. the vehicle-treated animals.
doi:10.1371/journal.pone.0021853.t004
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NO-sGC-cGMP signaling cascade.
Recent studies have demonstrated that riociguat improves
pulmonary hemodynamics and prevents or even reverses struc-
tural remodeling including the right ventricular hypertrophy and
muscularisation of small pulmonary arteries in two experimental
models of PH, namely hypoxia-induced PH in mice and
monocrotaline-induced PH in rats [14]. Riociguat is currently
undergoing phase III clinical trials in patients with pulmonary
arterial hypertension and chronic thromboembolic PH. Clinical
phase IIb studies showed that riociguat is well tolerated, easily
administered and produces significant and long-lasting improve-
ments in pulmonary hemodynamics, exercise capacity and
functional class in patients with PH [13,18,19,20].
The vascular effects of riociguat are not limited to the
pulmonary vasculature [18]. We have very recently demonstrated,
for the first time, that riociguat provides marked protection against
cardiac and renal end-organ damage in experimental low-renin
and high-renin models of hypertension [15]. To further investigate
the therapeutic potential of riociguat, the present study was
designed with a focus on the cardio-renal consequences of a long-
term treatment with riociguat, including assessment of hemody-
namics, cardiac and renal morphology, cardiovascular hormones,
and mortality in Dahl/ss rats exposed to a high salt intake.
Moreover, we measured protein expression of pro-fibrotic
biomarkers (OPN, TIMP1 and PAI-1) to better characterize the
anti-fibrotic effects of riociguat.
Inbred Dahl/ss rats maintained on a high salt diet (8% NaCl)
are commonly used as a clinically relevant animal model to
investigate salt-sensitive hypertension and cardiac and renal end-
organ damage [21,22]. In our study, these animals developed
arterial hypertension and cardiac and renal hypertrophy and
remodeling with impaired systolic and renal functions. Morpho-
logically, cardiac and renal damage was characterized by vascular
lesions, interstitial fibrosis and glomerulosclerosis. In response to
riociguat, we found a significant attenuation of cardiac and renal
hypertrophy and fibrosis and improved renal function in the
Dahl/ss rats, as compared to the vehicle-treated animals. These
effects were accompanied by a corresponding improvement of
systolic cardiac function including fractional shortening. Impor-
tantly, sGC stimulation by riociguat resulted in a reduced
mortality in the Dahl/ss rats exposed to a high salt diet. Our
findings highlight the clinical relevance of the structural improve-
ments induced by riociguat and provide further evidence that sGC
stimulators might be utilized as a new therapeutic option for
management of arterial hypertension and heart failure.
Increased oxidative stress, associated with an imbalance
between pro-oxidants and antioxidants, is a risk factor for
developing various cardiac and renal diseases [23,24]. Essential
hypertension in humans and salt-sensitive hypertension in animal
models are associated with progressive renal damage and
increased formation of reactive oxygen species [23,25]. Manning
et al. [23] have reported an increased renal superoxide production
in Dahl/ss rats maintained on a high salt diet due to decreased
renal levels of antioxidants including superoxide (SOD). Further-
more, the same research group [24] has demonstrated that
treatment of Dahl/ss rats maintained on a high salt diet with the
SOD mimetic tempol decreased mean arterial blood pressure and
attenuated renal dysfunction. Moreover, St Lezin et al. [26] have
shown that urinary cGMP excretion is impaired in Dahl/ss rats
compared to control Dahl/sr rats. Whether this decrease in cGMP
production is due to decreased bioavailability of L-arginine (the
substrate for NO production), down-regulation or uncoupling of
the endothelial NO synthase (eNOS), inactivation of NO by
superoxide anion, increased plasma concentrations of the
endogenous eNOS inhibitor asymmetric dimethylarginine, down-
regulation of sGC and/or alteration of the redox state of sGC
through oxidative stress or a combination of all of the above is still
unclear. Chen and Sanders [27] have also demonstrated that NO
production is affected in Dahl/ss rats exposed to a high salt diet.
Treatment with L-arginine decreased blood pressure and
increased urinary cGMP excretion as a result of increased NO
production. However, the direct stimulation of sGC is likely to
offer a more advantageous approach in the setting of impaired NO
production.
Although sGC agonists selectively stimulate the native sGC
containing the reduced heme-moiety [12,16], increased cGMP
levels in urine in the present study indicate that riociguat might
also stimulate sGC under conditions of oxidative stress and
sensitize sGC to endogenously produced NO. Our results are in
agreement with the recent findings that the sGC stimulator BAY
41-2272 (a close chemical analogue of riociguat) increases renal
cGMP production and thereby improves renal NO-cGMP
signaling, and prevents progression of the anti-Thy-1-induced
chronic renal fibrosis [28]. Thus, the pharmacological enhance-
ment of renal cGMP levels by sGC stimulation might provide
protection against renal injury.
Histopathological analysis revealed strong anti-remodeling
effects of riociguat as demonstrated by decreased tissue fibrosis
and hypertrophy in the heart and kidneys. It is important to
mention that these structural changes were also observed in the
low-dose riociguat group. Masuyama et al. [29] tested the
therapeutic potential of stimulating sGC with BAY 41-2272
administered for 14 days at a low dose (which had no effect on
blood pressure) in a rat model of the angiotensin II-induced
hypertension and cardiac remodeling. BAY 41-2272 prevented the
angiotensin II-induced cardiac remodeling and fibrosis via a local,
cGMP-dependent mechanism. In our study, a marked reduction
of myocyte diameter was observed in the Dahl/ss rats treated with
riociguat as compared with the animals receiving vehicle alone. In
addition, riociguat attenuated interstitial fibrosis and glomerulo-
sclerosis. These effects of riociguat in the salt-loaded Dahl/ss rats
are consistent with previous studies in the L-NAME-treated renin
transgenic rats and the 5/6 nephrectomized rats, where riociguat
showed potent protection against cardiac and renal organ damage
[15]. In agreement with these findings, plasma and urine protein
levels of the pro-fibrotic biomarkers OPN, TIMP-1 and PAI-1
were elevated in the vehicle group and markedly decreased by
riociguat, ultimately resulting in preservation of cardiac and renal
functions. Masuyama et al. [29] have also showed that BAY 41-
2272 downregulates collagen I and transforming growth factor
mRNA levels in the left ventricle in a rat model of the angiotensin
II-induced hypertension. Moreover, Peters et al. [28] have
reported a decrease in collagen accumulation, protein and mRNA
expression of TGF-b1, fibronectin, and PAI-1 by BAY 41-2272 in
a model of progressive anti-Thy1-induced chronic glomeruloscle-
Figure 2. Effects of riociguat on mRNA expression of osteopontin (OPN), plasminogen activator inhibitor-1 (PAI-1) and tissue
inhibitor of matrix metalloproteinase-1 (TIMP-1) in the left ventricle and the renal cortex in the vehicle (n=7) - and riociguat-
treated (3 or 10 mg/kg/d, n=11 per group) Dahl/ss rats maintained on a high-salt diet. Healthy, age-matched animals were used as
controls (n=10). Data are mean6SEM; *p,0.05 vs. the vehicle-treated animals; #p,0.05 vs. healthy controls.
doi:10.1371/journal.pone.0021853.g002
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studies could be used to monitor clinical efficacy of this new class
of drugs.
The relationship between the NO-sGC-cGMP pathway and
profibrotic biomarker expression remains to be elucidated.
Johnson et al. [30] have observed that OPN expression in Dahl
rats strongly correlates with the degree of hypertension and,
furthermore, that OPN is a potent inhibitor of inducible NO
synthase expression. In patients, circulating levels of OPN, PAI-1,
and TIMP-1 increase with the progression of chronic heart failure
and PH [4,5]. In addition, OPN expression coincides with tissue
degeneration in the myocardium and coronary arteries, and its
cytokine-like mode of action promotes tissue remodeling via
binding to integrins and modulation of extracellular matrix
formation [3,4]. Similarly, an increased expression PAI-1 and
TIMP-1 that contributes to extracellular matrix deposition has
been observed in the hearts and kidneys of patients with chronic
heart and kidney failure [2,7–10,1,31]. A direct molecular
mechanism linking sGC stimulation and regulation of the
expression of these genes has not been identified yet. Importantly,
the sGC stimulator riociguat markedly reduced the expression of
OPN, PAI-1 and TIMP-1 in the present model of chronic volume-
and pressure-overload in Dahl/ss rats.
There are some limitations of our study. First, the histopath-
ological analysis revealed marked kidney damage but the renal
function was not as much affected as expected. Secondly, healthy
control rats could have been included for baseline hemodynamic
measurements and analyses of plasma and urinary biochemical
parameters. However, several previous studies have also demon-
strated stable baseline data in healthy animals, as well as impaired
renal function and concomitant tissue remodeling in the heart and
kidneys in the Dahl/ss rats maintained on a high-salt diet
[22,32,33,34].
In conclusion, the present study demonstrates that the sGC
stimulator riociguat attenuates systemic hypertension and cardiac
and renal fibrotic tissue degeneration, improves systolic heart
function and markedly increases survival in a model of chronic
volume- and pressure-overload in Dahl/ss rats. These protective
effects are accompanied by decreased expression of the pro-
fibrotic biomarkers OPN, TIMP-1 and PAI-1, which have been
shown to correlate with the severity of cardiovascular diseases and
end-organ damage in clinical studies. Further studies are needed to
clarify the relationship between these biomarkers and the NO-
sGC-cGMP pathway. Our study provides an important step
towards the clinical evaluation of the cardio-renal protective
properties of sGC stimulators.
Materials and Methods
Chemicals
The sGC stimulator riociguat (BAY 63-2521; methyl-4,
6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-
pyrimidin-5-ylmethylcarbamate) was synthesized as previously
described [11].
Animal model and treatments
This investigation conforms to the national Guide for the Care
and Use of Laboratory Animals (Deutsches Tierschutzgesetz, May
18
th, 2006) and EU directives (86/609) and was approved by a
regional authority (Bezirksregierung Du ¨sseldorf, Germany, Permit
No. 50.05-240-26/05, No. 400/A14, approval date: March 21,
2005). Fifty seven 8-weeks old male Dahl salt sensitive (Dahl/ss)
rats (Charles River Laboratories, Sulzfeld, Germany) were studied.
Forty seven animals were fed a high-salt diet containing 8% NaCl
(w/w) (Commercial diet Sniff, Soest, Germany) and randomly
assigned to three treatment groups: vehicle alone (n=21),
riociguat 3 mg/kg/d (n=13), and riociguat 10 mg/kg/d
(n=13). A separate age-matched control group (n=10) was fed
a standard diet without NaCl supplementation and used for
baseline mRNA and protein quantification of the pro-fibrotic
biomarkers. Riociguat was administrated once a day for 14 weeks
by oral gavage in a suspension composed of Transcutol (10%),
Cremophor (20%), and water (70%) in a volume of 2 ml/kg. The
vehicle and control groups received only the Transcutol/
Cremophor suspension.
Systolic blood pressure and heart rate were measured non-
invasively via tail-cuff method (TSE Europe, Bad Homburg,
Germany), and the body weight was recorded weekly. Individual
Table 5. Histopathological evaluation of the hearts and kidneys from the vehicle- and riociguat-treated Dahl/ss rats maintained on
a high-salt diet.
Vehicle (n=17) Riociguat (3 mg/kg/d) (n=13) Riociguat (10 mg/kg/d) (n=13)
Glomerulosclerosis (score) 3.0360.39 2.6360.06** 2.5660.04***
Renal interstitial fibrosis (%) 3.0460.08 2.5060.08*** 2.1460.09***
Renal perivascular fibrosis (%) 2.9260.04 2.3460.06*** 2.2060.04***
Myocyte diameter (mm) 11.2061.3 9.9960.93** 9.1460.69***
Cardiac interstitial fibrosis (%) 1.9360.31 0.8260.14** 0.9560.16*
Cardiac perivascular fibrosis (%) 2.5760.18 2.3360.10 2.5561.00
Data are mean6SEM;
*p,0.05,
**p,0.01,
***p,0.001 vs. the vehicle-treated animals.
doi:10.1371/journal.pone.0021853.t005
Figure 3. Effects of riociguat on plasma and urinary protein levels of osteopontin (OPN), plasminogen activator inhibitor-1 (PAI-1)
and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in the vehicle (n=7) - and riociguat-treated (3 or 10 mg/kg/d, n=11 per
group) Dahl/ss rats maintained on a high-salt diet. Healthy, age-matched animals were used as controls (n=10). Data are mean6SEM;
*p,0.05, **p,0.01, ***p,0.001 vs. the vehicle-treated animals; ##p,0.01, ###p,0.001 vs. healthy controls.
doi:10.1371/journal.pone.0021853.g003
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cage collectors (Techiplast, Hohenpeissberg, Germany) on day 0
and at the end of the study.
At the study end, the animals were euthanized with intraper-
itoneal injection of pentobarbital, and blood samples were
obtained. Hearts and kidneys were harvested, weighed and used
for histological evaluation, and the tissue samples were taken for
mRNA isolation and quantification of biomarker expression.
Echocardiographic studies
High resolution transthoracic echocardiography (Sequia 512;
Acuson, Mountain View, CA) was performed under isoflurane (2–
2.5%) anesthesia at weeks 0 and 14. A 15-MHz linear array
transducer was placed gently on the shaved right hemithorax.
Parasternal left ventricular end-systolic and end-diastolic diameters
and wall thickness were measured in the short axis view at the level
of the papillary muscles using two dimensional guided M-mode
imaging. The measurements were performed in accordance with
the recommendations of the American Society of Echocardiogra-
phy. Fractional shortening (FS) was caculated using the equation:
FS (%)=((LVDd-LVDs)/LVDd)*100, where LVDd is the left
ventricular diameter in diastole and LVDs is the left ventricular
diameter in systole [35]. All measurements were performed offline
in DICOM-format by using SonoWin 4.1.6 (Meso, Mittweider,
Germany).
mRNA quantification of biomarkers by RTPCR
Tissue samples of the left ventricle myocardium or the renal
cortex (approximately 26262 mm) were cut off, immediately
frozen on dry ice and stored at 280uC. Frozen tissue samples were
ground in liquid nitrogen and extracted in 900 ml TrizolH
(Invitrogen, Karlsruhe, Germany) according to the protocol
provided by the manufacturer using glass bead homogenization
in a FastPrep FP120 Bio-101 Savant vibration mill (MP
Biochemicals, Eschwege, Germany). Subsequent to phenol-
chloroform extraction and precipitation by isopropanol, DNA
was eliminated from RNA samples by deoxyribonuclease I digest
(Cat. No. 18068-015; Invitrogen, Karlsruhe, Germany). The
ImProm-II TM Kit (Cat. No. A3800; Promega, Mannheim,
Germany) was used for reverse transcription and first-strand
cDNA synthesis. Real-time quantitative polymerase chain reac-
tions (RTPCR) using the ABI Prism 7700 Sequence Detection
System (Applied Biosystems, Carlsbad, CA) were performed to
determine relative gene expression of OPN, TIMP-1, PAI-1.
cDNA samples were amplified with a PCR mix containing Taq
polymerase (qPCR MasterMix Plus, Ref. RT-QP2x-03-075+;
Eurogentec, Seraing, Belgium) and primer sets with 6-FAM and
TAMRA labeled probes (Operon Biotechnologies, Cologne,
Germany) in 96-well or 384-well microtiter plates. 1–10 ng of
cDNA samples were run in triplicates in reaction volumes of 25 ml
(96-well MTP) or 20 ml (384-well MTP) under standard thermo-
cycler conditions.
TaqMan probe sets were generated from mRNA sequence data
(NCBI Genbank, U.S. National Library of Medicine, Bethesda,
MD) using Primer Express Software v2.0 (Applied Biosystems).
Relative gene expression was calculated using the delta Ct term
(Applied Biosystems, User Bulletin No. 2) related to endogenous
controls ribosomal protein L32 or beta-actin and Ct=35
threshold value. The primer probe sets were generated from the
following sequences (primers are listed for forward, reverse, and
probe sequence, respectively):
NM_013226 ribosomal protein L32 (CTTACTGTGCTGA-
GATTGCTC, CCAGCTGTGCTGCTCTTTCA, CAATGT-
GTCCTCTAAGAACCGAAAAGCCAT), V01217 cytoplasmic
beta-actin (ACCTTCAACACCCCAGCCA, CAGTGGTACGA-
CCAGAGGCA, ACGTAGCCATCCAGGCTGTGTTGTCC),
NM_009263 osteopontin (OPN, SPP1, AGCCATGACCACATG-
GACGA, GATTCGTCAGATTCATCCGAGT, AGACCATG-
CAGAGAGCGAGGA TTCTGTG), NM_008871 plasminogen
activator inhibitor-1 (Serpine1, PAI-1, GGCCGACTTCACA-
AGTCTTTC, CGCCACTGTGCCGCTCTCGT, ACCAAGA-
GCAGCTCTCTGTAGCACA), NM_053819 tissue inhibitor of
matrix metalloproteinase 1 (TIMP-1, CCGCAGCGAGGAGTT-
TCTC, GGCAGTGATGTGCAAATTTCC, TCGCGGGCC-
GTTTAAGGAA).
Plasma and urinary analyses
Plasma creatinine, urea, creatinine kinase (CK), lactate
dehydrogenase (LDH), glutamate dehydrogenase (GLDH), aspar-
tate amino transferase (AST), alanine amino transferase (ALT),
gamma-glutamyl tranferase (GGT), alkaline phosphatase (AP),
total protein, and albumin were analyzed using a multiple channel
analyzer (Synchron CX7; Beckmann, Hamburg) [36]. Atrial
natriuretic peptide (ANP), angiotensin I, B-type natriuretic peptide
(BNP), and plasma renin activity (PRA) were determined as
described previously [37]. Plasma concentrations of osteopontin
and TIMP-1 were quantified by enzyme linked immunosorbent
assays (ELISA) according to the instructions of the manufacturer
(R&D Systems, Minneapolis, MN), and total PAI-1 protein was
measured by an ELISA kit from Loxo (Dossenheim, Germany).
Urinary creatinine, urea, and total protein were analyzed on the
Synchron CX7multiple channel analyzer [36]. Urine volume was
measured gravimetrically and the excretion rates of sodium and
potassium were determined using an electrolyte analyzer (Instru-
mentation Laboratory, Bedford, MA), as described elsewhere [38].
The urine cyclic guanosine monophosphate (cGMP) concentra-
tions were measured using a commercially available radioimmu-
noassay kit (IBL, Hamburg, Germany). Individual urine samples
from the rats were vortexed and centrifuged prior to biomarker
quantification. The supernatants were diluted by an equal volume
of phosphate buffered saline (PBS), and 50 ml of diluted urine was
mixed with 50 ml of the sample buffer for detection of OPN, total
PAI-1 protein and TIMP-1 using the same ELISA kits as for
plasma analyses.
Histopathological evaluation
Hearts and kidneys of the vehicle- and riociguat-treated animals
were fixed in 10% neutral buffered formalin, embedded in
Paraplast A and sectioned. Sections were stained with hematoxylin
and eosin (H&E), Sirius Red, Periodic Acid-Schiff (PAS) and
Elastica-van Gieson. Quantitative stereology was performed using
a computer-aided image analysis system [39] and cardiac and
renal morphology (interstitial fibrosis, perivascular fibrosis and
glomerulosclerosis) were assessed as previously described [36,40].
The severity of interstitial and perivascular fibrosis was evaluated
following Sirius Red staining using computer-aided histomor-
phometry (Carl Zeiss Jenaoptik, Jena, Germany). PAS positive
material within the glomeruli was defined as glomerulosclerosis.
Perivascular fibrosis and glomerulosclerosis were assessed using a
semi-quantitative score by two independent investigators blinded
to the study groups. Microscopic pictures of kidney and heart
sections following Elastica-van Gieson staining were generated for
arterial blood vessel examination. The area contents of the media
and the lumen of renal or myocardial arteries were analyzed using
the ImageJ processing software developed at the National
Institutes of Health (Bethesda, MD), and the media-to-lumen
ratio was calculated serving as a marker for arterial wall
thickening. Myocyte diameter was determined using H&E stained
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software.
Statistical analysis
Data are presented as mean6SEM. The treatment effects were
tested using a one-way ANOVA followed by a Newman-Keuls post
hoc test, where appropriate (GraphPad Software 4.02, San Diego,
CA). Survival analysis was performed using Kaplan-Meier analysis
and the log-rank-test. A value of p,0.05 was considered
statistically significant.
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